Veracyte, Inc. (VCYT)
- Previous Close
19.85 - Open
19.88 - Bid 19.77 x 100
- Ask 19.85 x 300
- Day's Range
19.81 - 20.70 - 52 Week Range
18.61 - 30.52 - Volume
537,309 - Avg. Volume
665,914 - Market Cap (intraday)
1.489B - Beta (5Y Monthly) 1.64
- PE Ratio (TTM)
-- - EPS (TTM)
-1.02 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
30.83
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
www.veracyte.com815
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: VCYT
Performance Overview: VCYT
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VCYT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VCYT
Valuation Measures
Market Cap
1.49B
Enterprise Value
1.29B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.99
Price/Book (mrq)
1.43
Enterprise Value/Revenue
3.56
Enterprise Value/EBITDA
-26.03
Financial Highlights
Profitability and Income Statement
Profit Margin
-20.61%
Return on Assets (ttm)
-0.99%
Return on Equity (ttm)
-7.02%
Revenue (ttm)
361.05M
Net Income Avi to Common (ttm)
-74.4M
Diluted EPS (ttm)
-1.02
Balance Sheet and Cash Flow
Total Cash (mrq)
216.45M
Total Debt/Equity (mrq)
1.22%
Levered Free Cash Flow (ttm)
37.36M